Hypoxia - Pipeline Review, H2 2014
Summary
Global Markets Direct’s, ‘Hypoxia - Pipeline Review, H2 2014’, provides an overview of the Hypoxia’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Hypoxia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypoxia and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hypoxia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hypoxia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hypoxia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hypoxia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hypoxia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hypoxia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hypoxia Overview 6
Therapeutics Development 7
Pipeline Products for Hypoxia - Overview 7
Pipeline Products for Hypoxia - Comparative Analysis 8
Hypoxia - Therapeutics under Development by Companies 9
Hypoxia - Therapeutics under Investigation by Universities/Institutes 10
Hypoxia - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Hypoxia - Products under Development by Companies 13
Hypoxia - Products under Investigation by Universities/Institutes 14
Hypoxia - Companies Involved in Therapeutics Development 15
Baxter International Inc. 15
Hypoxia - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 22
Drug Profiles 24
Aes-103 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
F-15845 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Recombinant Protein to Activate Protein S100-A8 and S100-A9 for Immunology and Respiratory - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule to Antagonize Notch Receptor for Pulmonary Arterial Hypertension and Hypoxia - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Hypoxia - Recent Pipeline Updates 30
Hypoxia - Dormant Projects 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 34
Disclaimer 34
List Of Tables
List of Tables
Number of Products under Development for Hypoxia, H2 2014 7
Number of Products under Development for Hypoxia - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Hypoxia - Pipeline by Baxter International Inc., H2 2014 15
Assessment by Monotherapy Products, H2 2014 16
Number of Products by Stage and Target, H2 2014 18
Number of Products by Stage and Mechanism of Action, H2 2014 20
Number of Products by Stage and Route of Administration, H2 2014 21
Number of Products by Stage and Molecule Type, H2 2014 23
Hypoxia Therapeutics - Recent Pipeline Updates, H2 2014 30
Hypoxia - Dormant Projects, H2 2014 32
List Of Figures
List of Figures
Number of Products under Development for Hypoxia, H2 2014 7
Number of Products under Development for Hypoxia - Comparative Analysis, H2 2014 8
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Early Stage Products, H2 2014 12
Assessment by Monotherapy Products, H2 2014 16
Number of Products by Top 10 Targets, H2 2014 17
Number of Products by Stage and Top 10 Targets, H2 2014 17
Number of Products by Top 10 Mechanism of Actions, H2 2014 19
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 19
Number of Products by Top 10 Molecule Types, H2 2014 22
Number of Products by Stage and Top 10 Molecule Types, H2 2014 22
